Physician profile
Michael Navato
NPI 1235337668
$79,629.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $23K · 2021: $18K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $46,654.80 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $30,588.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $437.45 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $373.11 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $368.87 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $312.21 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $153.60 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.06 | 2019-2021 | |
| Lundbeck LLC | $100.83 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $87.24 | 2019-2021 | |
| Allergan, INC. | $81.61 | 2019-2020 | |
| Abbvie INC. | $71.62 | 2021 | |
| Eisai INC. | $71.02 | 2020 | |
| Neurocrine Biosciences, INC. | $65.99 | 2019-2021 | |
| Indivior INC. | $65.20 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $35.17 | 2019-2021 | |
| Shire North American Group INC | $33.96 | 2019 | |
| Noven Therapeutics, LLC | $13.81 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.39 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Navato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.